Key result
Novel pulmonary arterial hypertension therapies require adaptive trials and clinically meaningful composite endpoints.
Why the study?
Treatment options for pulmonary artery hypertension are neither universally available nor always effective, highlighting the need for novel therapies and therapeutic strategies.
Answers are grounded in this paper and cite their sources.
Future PAH research requires innovative trial designs, clinically meaningful composite endpoints, and exploration of novel pathways such as metabolism, inflammation, and cellular regeneration.
A greater understanding of the epidemiology, pathogenesis, and pathophysiology of pulmonary artery hypertension (PAH) has led to significant advances, but the disease remains fatal. Treatment options are neither universally available nor always effective, underscoring the need for development of novel therapies and therapeutic strategies. Clinical trials to date have provided evidence of efficacy, but were limited in evaluating the scope and duration of treatment effects. Numerous potential targets in varied stages of drug development exist, in addition to novel uses of familiar therapies. The pursuit of gene and cell-based therapy continues, and device use to help acute deterioration and chronic management is emerging. This rapid surge of drug development has led to multicenter pivotal clinical trials and has resulted in novel ethical and global clinical trial concerns. This paper will provide an overview of the opportunities and challenges that await the development of novel treatments for PAH.
No takes yet. Share an insight, caveat, or question.
Gomberg‐Maitland et al. (2013) conducted a review in Pulmonary artery hypertension. Novel therapies and trial designs was evaluated. Novel therapies and adaptive clinical trial designs are needed to advance the treatment of pulmonary artery hypertension, alongside the development of clinically meaningful composite endpoints.
Synapse has enriched 10 related papers. Consider them for comparative context: